Antimicrobial treatment for intra-abdominal infections

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 17, 2007, Pages 2933-2945

  Mazuski, John E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial drug resistance; Antimicrobial therapy; Intra abdominal abscess; Intra abdominal infection; Secondary peritonitis; Tertiary peritonitis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; FLUCONAZOLE; GENTAMICIN; MEROPENEM; METRONIDAZOLE; NETILMICIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TOBRAMYCIN; UNINDEXED DRUG;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL SURGERY; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; APPENDECTOMY; APPENDIX PERFORATION; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CANDIDA ALBICANS; CANDIDIASIS; CATHETER INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERITONITIS; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ABDOMINAL ABSCESS; ABDOMINAL CAVITY; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; PERITONITIS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 37349065160     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.17.2933     Document Type: Review

References (72)

1. CHEADLE WG, SPAIN DA: The continuing challenge of intra-abdominal infections. Am. J. Surg. (2003) 186:S15-S22.
2. MARSHALL JC: Intra-abdominal infections. Microbes Infect. (2004) 6:1015-1025.
3. BLOT S, DE WAELE JJ: Critical issues in the clinical management of complicated intra-abdominal infections. Drugs (2005) 65:1611-1620.
4. MARSHALL JC, INNES M: Intensive care unit management of intra-abdominal infection. Crit. Care Med. (2003) 31:2228-2237.
5. MAZUSKI JE: Clinical challenges and unmet needs in the management of complicated intra-abdominal infections. Surg. Infect. (2005) 6:S49-S69.
6. TELLADO JM, WILSON SE: Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg. Infect. (2005) 6:329-343.
7. ROEHRBORN A, THOMAS L, POTRECK O et al.: The microbiology of postoperative peritonitis. Clin. Infect. Dis. (2003) 33:1513-1519.
8. SOLOMKIN JS, HEMSELL DL, SWEET R et al.: Evaluation of new anti-infective drugs for the treatment of intra-abdominal infections. Clin. Infect. Dis. (1992) 15:S33-S42.
9. CALANDRA T, COHEN J: International sepsis forum definition of infection in the ICU consensus conference. The International sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit. Care Med. (2005) 33:1538-1548.
10. STRAUSS E, CALY WR: Spontaneous bacterial peritonitis: a therapeutic update. Expert Rev. Antiinfect. Ther. (2006) 4:248-260.
11. BROOK I: Microbiology of polymicrobial abscesses and implications for therapy. J. Antimicrob. Chemother. (2002) 50:805-810.
12. GOLDSTEIN EJC, SNYDMAN DR: Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J. Antimicrob. Chemother. (2004) 53:ii29-ii36.
13. CHOW JW, SATISHCHANDRAN V, SNYDER TA et al.: In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 study for monitoring antimicrobial resistance trends (SMART). Surg. Infect. (2005) 6:439-448.
14. TEPPLER H, MCCARROLL K, GESSER RM, WOODS GL: Surgical infections with Enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam. Surg. Infect. (2002) 3:337-349.
15. SITGES-SERRA A, LOPEZ MJ, GIRVENT M et al.: Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br. J. Surg. (2002) 89:361-367.
16. WAITES KB, DUFFY LB, DOWZICKY MJ: Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob. Agents Chemother. (2006) 50:3479-3484.
17. DELISLE S, PERL TM: Vancomycin-resistant enterococci: a road map on how to prevent the emergency and transmission of antimicrobial resistance. Chest (2003) 123:S504-S518.
18. ROTSTEIN OD, PRUETT TL, SIMMONS RL: Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can. J. Surg. (1986) 29:247-250.
19. NATHENS AB, ROTSTEIN OD, MARSHALL JC: Tertiary peritonitis: clinical features of a complex nosocomial infection. World J. Surg. (1998) 22:158-163.
20. GOLDSTEIN EJC: Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin. Infect. Dis. (2002) 35(Suppl. 1):S106-S111.
21. ALDRIDGE KE, ASHCRAFT D, CAMBRE K et al.: Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. (2001) 45:1238-1243.
22. TRICK WE, FRIDKIN SK, EDWARDS JR et al.: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989 - 1999. Clin. Infect. Dis. (2002) 35:627-630.
23. PFALLER MA, KIEKEMA DJ, RINALDI MG et al.: Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. (2005) 43:5848-5859.
24. MAZUSKI JE, SAWYER, RG, NATHENS AB et al.: The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg. Infect. (2002) 3:161-173.
25. SOLOMKIN JS, MAZUSKI JE, BARON EJ et al.: Guidelines for the selection of anti-infective agents for intra-abdominal infections. Clin. Infect. Dis. (2003) 37:997-1005.
26. FABIAN TC: Infection in penetrating abdominal trauma: risk ftctors and preventive antibiotics. Am. Surg. (2002) 68:29-35.
27. SNYDMAN DR, JACOBUS NV, MCDERMOTT LA et al.: Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob. Agents Chemother. (1999) 43:2417-2422.
28. MAZUSKI JE, SAWYER RG, NATHENS AB et al.: The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg. Infect. (2002) 3:175-233.
29. BAILEY JA, VIRGO KS, DIPIRO JT et al.: Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg. Infect. (2002) 3:315-335.
30. MUELLER EM, BOUCHER BA: The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate to severe infections encountered in critically ill surgical patients. Surg. Infect. (In Press).
31. GOLDSTEIN EJC, CITRON DM, WARREN YA et al.: In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. (2006) 50:148-155.
32. MALANGONI MA, SONG J, HERRINGTON J et al.: Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann. Surg. (2006) 244:204-211.
33. BABINCHAK T, ELLIS-GROSSE E, DARTOIS N et al.: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical data. Clin. Infect. Dis. (2005) 41(Suppl. 5):S354-S367.
34. ANAYA DA, NATHENS AB: Risk factors for severe sepsis in secondary peritonitis. Surg. Infect. (2003) 4:355-362.
35. HOPKINS JA, LEE JCH, WILSON SE: Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am. Surg. (1993) 59:791-796.
36. CHRISTOU NV, TURGEON P, WASSEF R et al.: Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch. Surg. (1996) 131:1193-1201.
37. MONTRAVERS P, GAUZIT R, MULLER C et al.: Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. (1996) 23:486-494.
38. KROBOT K, YIN D, ZHANG Q et al.: Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:682-687.
39. MERLINO JI, MALANGONI MA, SMITH CM, LANGE RL: Prospective randomized trials affect the outcomes of intraabdominal infection. Ann. Surg. (2001) 233:859-866.
40. COMETTA A, BAUMGARTNER JD, LEW D et al.: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. (1994) 38:1309-1313.
41. DUPONT H, CARBON C, CARLET J: The severe generalized peritonitis study group. Monotherapy with a broad-spectrum β-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob. Agents Chemother. (2000) 44:2028-2033.
42. AMERICAN THORACIC SOCIETY, INFECTIOUS DISEASES SOCIETY OF AMERICAN: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171:388-416.
43. BURNETT RJ, HAVERSTOCK DC, DELLINGER EP et al.: Definition of the role of enterococcus in intra-abdominal infection: analysis of a prospective randomized trial. Surgery (1995) 118:716-723.
44. SOTTO A, LEFRANT JY, FABBRO-PERAY P et al.: Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J. Antimicrob. Chemother. (2002) 50:569-576.
45. HARBARTH S, UCKAY I: Are there patients with peritonitis who require empiric therapy for Enterococcus? Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:73-77.
46. TORRES-VIERA C, DEMBRY LM: Approaches to vancomycin-resistant enterococci. Curr. Opin. Infect. Dis. (2004) 17:541-547.
47. ELIOPOULOS GM: Antimicrobial agents for treatment of serious infections cause by resistant Staphylococcus aureus and enterococci. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:826-831.
48. CONNOR S, ALEXAKIS N, NEAL T et al.: Fungal infection but not type of bacterial infection is associated with a high mortality in primary and secondary infected pancreatic necrosis. Dig. Surg. (2004) 21:297-304.
49. SOLOMKIN JS: Antibiotic resistance in postoperative infections. Crit. Care Med. (2001) 29:N97-N99.
50. SOLOMKIN JS, BJORNSON HS, CAINZOS M et al.: A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am. J. Surg. (2004) 187:134-145.
51. JOHN MA, PLETCH C, HUSSAIN Z: In vitro activity of quinupristin/ dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J. Antimicrob. Chemother. (2002) 50:933-938.
52. KING A, PHILLIPS I: The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J. Antimicrob. Chemother., (2001) 48:219-223.
53. CARPENTER CF, CHAMBERS HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. (2004) 38:994-1000.
54. BASSETTI M, RIGHI E, TUMBARELLO M et al.: Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev. Antiinfect. Ther. (2006) 4:875-885.
55. SPANAKIS EK, APERIS G, MYLONAKIS E: New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. (2006) 43:1060-1068.
56. ABELE-HORNE M, KOPP A, STERNBERG U et al.: A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection (1996) 24:426-432.
57. MASCHMEYER G: The changing epidemiology of invasive fungal infections: new threats. Int. J. Antimicrob. Agents (2006) 27S:S3-S6.
58. BOCHUD PY, BONTEN M, MARCHETTI O, CALANDRA T: Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit. Care Med. (2004) 32:S495-S512.
59. DRAGO M, SCALTRITO MM, MORACE G et al.: In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:619-624.
60. PFALLER MA, MESSER SA, BOYKEN L et al.: Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. (2003) 41:5729-5731.
61. EGGIMAN P, FRANCIOLI P, BILLE J et al.: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med. (1999) 27:1066-1072.
62. CALANDRA T, BILLE J, SCHNEIDER R et al.: Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet (1989) 2(8677):1437-1440.
63. SANDVEN P, GIERCKSKY KE, NORGAS GROUP, NORWEGIAN YEAST STUDY GROUP: Yeast colonization in surgical patients with intra-abdominal perforations. Eur. J. Clin. Microbiol. Infect. Dis. (2001) 20:475-481.
64. RAYMOND DP, KUEHNERT MJ, SAWYER RG: Preventing antimicrobial-resistant bacterial infections in surgical patients. Surg. Infect. (2002) 3:375-385.
65. GLEISNER AL, ARGENTA R, PIMENTEL M et al.: Infective complications according to duration of antibiotic treatment in acute abdomen. Int. J. Infect Dis. (2004) 8:155-162.
66. SCHEIN M, ASSALIA A, BACHUS H: Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br. J. Surg. (1994) 81:989-991.
67. ANDÅKER L, HÖJER H, KIHLSTRÖM E, LINDHAGEN J: Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir. Scand. (1987) 153:185-192.
68. SMITH JA, BELL GA, MURPHY J et al.: Evaluation of the use of a protocol in the antimicrobial treatment of intra-abdominal sepsis. J. Hosp. Infect. (1985) 6:60-64.
69. TAYLOR E, DEV V, SHAH D et al.: Complicated appendicitis: is there a minimum intravenous antibiotic requirement? a prospective randomized trial. Amer. Surg. (2000) 66:887-890.
70. LENNARD ES, MINSHEW BH, DELLINGER EP, WERTZ M: Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch. Surg. (1980) 115:918-921.
71. LENNARD ES, DELLINGER EP, WERTZ MJ, MINSHEW BH: Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann. Surg. (1982) 195:19-24.
72. VISSER MR, BOSSCHA K, OLSMAN J et al.: Predictors of recurrence of fulminant bacterial peritonitis after discontinuation of antibiotics in open management of the abdomen. Eur. J. Surg. (1998) 164:825-829.